Hypoadiponectinemia and Insulin Resistance are Associated with Nonalcoholic Fatty Liver Disease by Yoon, Dokyoung et al.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a clinicopatho-
logical syndrome characterized by hepatic steatosis with or
without active inflammation (1) in patients with a negligible
alcohol intake. There is growing concern about NAFLD,
not only because this is a common liver disorder with a world-
wide distribution, but also because it is recognized as one of
the leading causes of chronic liver disease (2). In addition, a
recent study has revealed that patients with nonalcoholic
steatohepatitis (NASH) may progress to liver fibrosis, and
approximately 8-17% progress to cirrhosis (2, 3). Although
NAFLD may occur in non-obese patients (1), most cases of
NAFLD are associated with obesity, type 2 diabetes mellitus
(4), and hyperlipidemia (5). Weight reduction alone can im-
prove liver function in obese patients with fatty liver (6). More-
over, insulin resistance underlies most cases of NAFLD, using
the homeostasis model assessment-insulin resistance (HOMA-
IR) method (7, 8), with a resultant increase in circulating in-
sulin levels (9).
Adiponectin is a 30-kDa protein (10). In normal humans,
its expression is restricted to adipose tissue (11). Plasma adi-
ponectin levels are negatively correlated with the body mass
index (BMI), fasting plasma glucose, fasting insulin, insulin
resistance, and triglycerides (12). It is an anti-inflammatory
adipocytokine that modulates insulin effects (13). The admin-
istration of adiponectin to mice decreased the plasma glucose
(10), free fatty acid (FFA) and triglyceride levels (14), and hep-
atic glucose production (13). Plasma adiponectin levels are
directly correlated with insulin sensitivity and, consequently,
with decreases in obese and type 2 diabetic patients (11, 15).
Since adiponectin appears to induce insulin sensitivity, we
hypothesized that hypoadiponectinemia is associated with
NAFLD. Therefore, we investigated the relationship between
NAFLD and plasma adiponectin levels and insulin resistance.
MATERIALS AND METHODS
The study subjects were recruited from participants in rou-
tine health examinations at the Department of Family Medi-
cine, Korea University Hospital, Seoul, Korea, in February
2004. The study was approved by the ethics committee of
Anam Hospital, and was conducted in conformity with the
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Hypoadiponectinemia and Insulin Resistance are Associated with 
Nonalcoholic Fatty Liver Disease
We investigated the association between nonalcoholic fatty liver disease (NAFLD)
and plasma adiponectin levels and insulin resistance. We recruited study subjects
among one hundred and eighty one persons who were examined abdominal ultra-
sound at routine screening tests. A standard interview (consumption of alcohol and
medical history), physical examination (height, weight, waist circumference, and
blood pressure), and biochemical study (lipid parameters, aminotransferases, fast-
ing plasma glucose, fasting insulin, and plasma adiponectin) were performed. Sub-
jects who consumed alcohol more than moderate, evidence of viral hepatitis, toxic
hepatitis, and serious cardiac, renal, or hepatic disease were excluded. Thirty-eight
NAFLD patients and 53 control subjects diagnosed by ultrasound were finally ana-
lyzed. The plasma adiponectin level was significantly correlated with HDL-cholesterol
(r=0. 38, p<0.001), triglycerides (r=-0.22, p=0.04), fasting insulin (r=-0.37, p<0.01),
and insulin resistance by homeostasis model of assessment-insulin resistance (HOMA-
IR) (r=-0.39, p<0.01), after adjusting for age, sex, and adiposity. Multiple logistic
regression analysis indicated that HOMA-IR was a significant predictor of having
NAFLD (odds ratio [OR]=2.38; 95% confidence interval [CI]: 1.52-5.74), while adipo-
nectin had a protective effect against NAFLD (OR=0.22; 95% CI: 0.09-0.55). We
demonstrated that hypoadiponectinemia and insulin resistance are associated with
NAFLD independent of obesity. 
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Helsinki Declaration. Written informed consent was obtained
from all the participants before commencing the study. 
One hundred and eighty one subjects were screened. After
a standard interview (consumption of alcohol, medication,
and disease history), forty four subjects who consumed alco-
hol more than twice per week, or more than 20 g per week,
were excluded. Ten patients who had pathologic findings
such as liver cirrhosis on ultrasound were also excluded. Six-
teen subjects with evidence of viral hepatitis, toxic hepatitis,
and serious cardiac, renal, or hepatic disease were excluded.
Of the remaining subjects, after excluded elderly than seven-
ties, 38 subjects with a ‘bright liver’ at ultrasonography were
allocated as NAFLD group, while the 53 subjects with a
‘normal liver’ were assessed as control group.
Height (cm) and weight (kg) were measured to calculate
body mass index (BMI) as weight (kg)/height (m2). Waist
circumference was the minimum circumference between the
costal margin and iliac crest. Body fat (%) was measured in
a bioimpedance analysis (Inbody 3.0, Biospace, Seoul, Korea).
Blood pressure was measured using a standard mercury sphyg-
momanometer, after the subjects were allowed to rest for at
least 10 min.
Blood was obtained after a 12-hr overnight fast. A routine
biochemical evaluation was performed, including serum aspar-
tate aminotransferase (AST), alanine aminotransferase (ALT),
total cholesterol, HDL-cholesterol, triglyceride, LDL-choles-
terol, fasting plasma glucose, and fasting insulin. Serum was
recovered from the supernatant after centrifuging it at 3,000
rpm for 15 min using a clinical centrifuge. The index of insulin
resistance was measured using the homeostasis model of assess-
ment (HOMA) method, as HOMA-IR (%)=fasting glucose/
18× insulin/22.5, with insulin expressed in  U/mL and fast-
ing glucose in mg/dL (16).
The adiponectin protein levels in human plasma were quan-
tified using a commercially available enzyme-linked immu-
nosorbent assay (ELISA) kit (Quantikine) from R&D Systems
(Minneapolis, MN, U.S.A.) after each serum sample was dilut-
ed 100-fold, according to the manufacturer’s instructions.
All the subjects were given an ultrasound scan of the liver
by an experienced radiologist who was blinded to the labo-
ratory values. The diagnosis of fatty liver was based on abnor-
mally intense, high-level echoes arising from the hepatic
parenchyma, with amplitude similar to that of echoes aris-
ing from the diaphragm.
The results are expressed as the mean±SD for Gaussian
variables and as median and lower and upper quartiles for
non-Gaussian variables. Parameters that did not fulfill nor-
mal distribution (i.e., fasting insulin, HOMA-IR, adiponectin)
were log-transformed for subsequent analysis. Anthropometric
and metabolic characteristics for normally distributed data
between control group and NAFLD group were compared
by Student t-test and the Wilcoxon two-sample test for data
not normally distributed according to sex. 
Pearson correlation and partial correlation analyses were
used to test the associations between plasma adiponectin levels
and anthropometric and metabolic characteristics after adjust-
ing for age, sex, and adiposity (BMI, waist circumference,
and fat mass). 
Multiple logistic regression analysis was used to determine
the factors more closely associated with NAFLD, using the
Variables
Men
Control NAFLD p value
Women
Control NAFLD p value
Number (%) 15 (58) 11 (42) 38 (58) 27 (42)
Age (yr)  45.3±11.7 51.8±6.5 0.33 49.3±8.4 54.2±8.2 0.19
BMI (kg/m
2) 23.7±1.8 24.5±2.1 <0.01 26.0±2.1 27.1±3.5 <0.01
Waist circumference (cm)  85.3±5.7 81.6±6.9 0.02 83.6±12.6 88.6±8.7 0.01
Body fat mass (%)  19.0±3.2 31.5±4.3 <0.01 23.5±4.5 34.4±5.8 0.03
Systolic BP (mmHg) 122.1±21.5 118.5±10.1 0.96 122.5±13.6 124.8±14.8 0.05
Diastolic BP (mmHg)  72.5±14.1 74.5±9.9 0.15 79.6±9.25 79.3±9.1 0.05
Total cholesterol (mg/dL) 199.4±43.3 207.8±42.3 0.62 198.3±35.3 204.6±31.4 0.45
HDL-cholesterol (mg/dL)  46.6±10.4 41.1±6.7 0.12 57.1±17.1 49.4±12.9 0.04
LDL-cholesterol (mg/dL) 124.9±32.8 129.3±39.6 0.76 117.0±28.7 127.3±24.7 0.14
Triglycerides (mg/dL)  137.8±78.7 204.7±46.4 0.01 133.2±70.7 159.8±74.5 0.15
AST (U/L)  19.4±4.8 22.5±4.3 0.10 23.6±18.3 25.9±9.1 0.55
ALT (U/L) 21.6±7.3 28.7±10.1 0.05 23.2±30.5 32.0±19.0 0.15
Fasting blood glucose (mg/dL) 94.3±11.4 93.2±11.8 0.84 89.9±9.1 96.1±16.1 0.05
Fasting insulin ( U/mL)  5.92 (5.20-8.17) 8.19 (7.00-9.43) 0.04 6.81 (5.84-8.83) 9.01 (7.71-13.90) <0.01
HOMA-IR 1.40 (1.17-1.80) 1.99 (1.56-2.40) 0.04 1.56 (1.24-2.01) 2.31 (1.69-3.23) <0.01
Adiponectin ( g/mL)  5.58 (3.92-8.70) 2.50 (2.02-3.84) <0.01 8.38 (5.15-12.11) 6.17 (3.69-9.52) <0.01
Table 1. Anthropometric and metabolic variables of NAFLD and control groups in men and women, respectively
Data are expressed as mean±SD for Gaussian variables and median and lower and higher quartile for non-Gaussian variables.
NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; BP, blood pressure; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-choles-
terol, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HOMA-IR, homeostasis model of assess-
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presence of NAFLD as the dependent variable, and adiponec-
tin, BMI, waist circumference, HOMA-IR, age, and sex as
independent variables. The level of statistical significance was
set at p<0.05. All statistical analyses were carried out using the
SAS computer analysis program (version 8.2; SAS Institute).
RESULTS
Anthropometric and metabolic characteristics of NAFLD
and control groups in men and women, respectively, in Table
1. The study subjects were included 26 men and 65 women.
The mean age was 51.3±8.8 yr and the mean BMI was 25.3
±2.9 kg/m2. There was no significant difference in plasma
adiponectin levels as well as other clinical parameters between
control group and non-participants of this study. NAFLD
subjects had significantly higher BMI, waist circumference,
fat mass, fasting insulin, and HOMA-IR, and had significantly
lower plasma adiponectin than control groups. Log levels of
plasma adiponectin were significantly lower in men than in
women (0.50±0.35 and 1.34±0.54, respectively, p<0.001).
Fig. 1 indicates plasma adiponectin levels and HOMA-IR
in the NAFLD and control groups in men and women, respec-
tively. Plasma adiponectin levels in NAFLD group were sig-
nificantly lower than those in control group in both men and
women. HOMA-IR in NAFLD group were significantly
higher than those in control group in both men and women.
Fig. 2 graphically depicts the correlations of plasma adipo-
nectin levels with HOMA-IR and waist circumference accord-
ing to sex. Plasma adiponectin levels were significantly inverse
correlated (r=-0.45, p<0.01) with HOMA-IR in women. In
the other hands, the associations of plasma adiponectin levels
with waist circumference was significantly inverse correlated
in both men and women (r=-0.35 p=0.03, r=-0.41 p<0.01,
respectively)
The univariate correlations and partial correlation analyses
after adjusting for age, sex, and adiposity (BMI, waist circum-
ference, and fat mass) between plasma adiponectin levels and
anthropometric and metabolic parameters are shown in Table
2. Adiponectin levels correlated with waist circumference
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Fig. 1. Plasma adiponectin levels (A) and HOMA-IR (B) in NAFLD and control groups in men and women, respectively. Closed bars, NAFLD
group; Open bars, Control groups.
*p<0.05.
Fig. 2. Correlations of plasma adiponectin levels between HOMA-IR (A) and waist circumference (B) in men (open circle) and women (closed
circle), respectively.
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(r=-0.42, p<0.01), fat mass (r=-0.29, p<0.01), HDL-choles-
terol (r=0.50, p<0.01), triglyceride (r=-0.31, p<0.01), and
HOMA-IR (r=-0.34, p<0.01) in univariate analyses. Partial
correlation analyses showed a significant positive correlation
between plasma adiponectin levels and HDL-cholesterol levels
(r=0.38, p<0.01). Conversely, negative correlations were ob-
served between the plasma adiponectin levels and diastolic
blood pressure (r=-0.22, p=0.04), triglycerides (r=-0.22, p=
0.04), fasting insulin (-0.37, p<0.01), and HOMA-IR (r=-0.39,
p<0.01).
Table 3 shows the multivariate logistic regression analysis
in which the presence of NAFLD was used as the dependent
variable, while all variables were designated the independent
variables. HOMA-IR indicative of insulin resistance, plasma
adiponectin level, BMI, and waist circumference were inde-
pendent factors significantly associated with NAFLD. The
odds ratios for NAFLD with BMI (odds ratio [OR]=1.45;
95% confidence interval [CI]: 1.19-1.76), waist circumfer-
ence (OR=1.13; 95% CI: 1.04-1.22), HOMA-IR (OR=2.38;
95% CI: 1.52-5.74), and plasma adiponectin levels (OR=
0.22; 95% CI: 0.09-0.55) was statistically significant in mul-
tiple regression analysis that included all variables.
DISCUSSION
We found that the NAFLD group had a higher insulin
resistance than the control group, which is in agreement with
previous studies (17, 18). NAFLD is associated with insulin
resistance and hyperinsulinemia in even lean subjects with
normal glucose tolerance (18). It was suggested that insulin
resistance is the pathognomonic condition responsible for
NAFLD. Indeed, NAFLD is considered the hepatic manifes-
tation of metabolic syndrome. 
Insulin resistance is an essential requirement of NASH,
independent of the degree of obesity (12). The insulin-sen-
sitizing drugs troglitazone (19) and metformin (20) reduce
aminotransferase levels. In the insulin-resistant state, accel-
erated lipolysis of adipose tissue results in an increased sup-
ply of hepatic free fatty acids (FFAs) and increased lipid oxi-
dation, this is accompanied by fat accumulation in hepato-
cytes. There is a good correlation between the liver fat con-
tent and liver insulin resistance in normal subjects and in
type 2 diabetic patients (20).
In this study, insulin resistance was measured using the
homeostasis model assessment method, although euglycemic-
hyperinsulinemic clamp is the gold standard for defining
insulin resistance (7, 8). However, HOMA-IR is easy to per-
form, and that method is highly correlated with the euglyce-
mic-hyperglycemic clamp (r=0.83, p<0.01) (21). The HOMA
method for measuring insulin resistance has been applied
extensively in epidemiological investigations (7, 8, 21).
Our study confirms that hypoadiponectinemia occurs in
subjects with NAFLD, after controlling for age, sex, and
adiposity. Animal models have indicated that adiponectin
confers protective effects against alcoholic and nonalcoholic
fatty liver disease (22, 23). Recent study reported that hypoad-
iponectinemia is a feature of NASH independent of insulin
resistance and reduced adiponectin level is associated with
more extensive necroinflammation and may contribute to
the development of necroinflammatory forms of NAFLD (24).
These data might also support the hypothesis that adiponectin
has hepatoprotective effects in humans with NAFLD. The
most likely reason for low adiponectin levels in NAFLD may
be insulin resistance. 
Our study found that HOMA-IR was significantly nega-
tively correlated to adiponectin levels which were in accord
with a previous report (25). Many investigators (8, 26, 27)
suggest that adiponectin regulates hepatocyte metabolism
BMI, body mass index; BP, blood pressure; AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase; HDL-cholesterol, high-density
lipoprotein cholesterol; HOMA-IR, homeostasis model of assessment-
insulin resistance.
*Log transformation values. 
� adjusted for age, sex, and adiposity (BMI,
waist circumference, fat mass).
Variable
Crude 
r (p-value)
Partial
�
r (p-value)
Age 0.15 (0.16)
BMI -0.11 (0.29)
Waist circumference -0.42 (<0.01)
Fat mass -0.29 (<0.01)
Systolic BP  -0.07 (0.48) -0.10 (0.36)
Diastolic BP  -0.17 (0.10) -0.22 (0.04)
AST  -0.01 (0.94) -0.07 (0.54)
ALT  -0.11 (0.29) -0.12 (0.26)
Total cholesterol  0.06 (0.56) 0.08 (0.47)
HDL cholesterol  0.50 (<0.01) 0.38 (<0.01)
Triglycerides  -0.31 (<0.01) -0.22 (0.04)
Fasting plasma glucose  0.10 (0.33) -0.07 (0.49)
Fasting insulin  -0.31 (<0.01) -0.37 (<0.01)
HOMA-IR*  -0.34 (<0.01) -0.39 (<0.01)
Table 2. Crude and partial correlation between plasma adipo-
nectin levels* and clinical parameters in the study subjects
BMI, body mass index; HOMA-IR, homeostasis model of assessment-
insulin resistance.
*Log transformation values.
Variable
Regression
coefficient
S.E.
p-
value
Odds
ratio
95% C.I.
Intercept -7.96 2.77 <0.01
BMI 0.40 0.11 <0.01 1.45 1.19-1.76
Waist circumference  0.12 0.04 <0.01 1.13 1.04-1.22
HOMA-IR* 1.52 0.86 <0.01 2.38 1.52-5.74
Adiponectin* -1.53 0.47 <0.01 0.22 0.09-0.55
Table 3. Odds ratio for NAFLD as a dependent variable and
anthropometric measurements, insulin resistance and plasma
adiponectin levels as independent variables by stepwise multi-
variate logistic regression analysis directly. Long-term administration of adiponectin to diabetic
mice improved the indices of insulin sensitivity, and decreased
liver, muscle, and plasma triglycerides, and FFAs (22). Injec-
tion of recombinant adiponectin in mice increases fatty acid
oxidation in muscle, reduces triglyceride content in muscle,
and improves muscle sensitivity to insulin (14). 
Raised plasma tumor necrosis factor (TNF)- is thought
to be another reason for the low adiponectin levels in NAFLD
(28). Overproduction of the proinflammatory cytokine TNF-
by adipose tissue is involved in insulin resistance in obesity
and TNF- is a major cytokine contributing to liver damage
in NAFLD (29). 
In our study, plasma adiponectin levels were elevated more
in women than in men. Similar results have been reported
in several studies (29, 30), while others failed to observe a sex
difference (31). The higher adiponectin expression in women,
as compared to men, might be due to the fact that women
tend to have less visceral fat tissue than subcutaneous fat tis-
sue. Plasma adiponectin levels were determined predomi-
nantly by visceral fat, not by subcutaneous fat (32). There-
fore, sexual dimorphism of the body fat distribution might
contribute to the difference in plasma adiponectin levels in
women and men. 
Among the anthropometric index, waist circumference was
stronger correlation with plasma adiponectin level, in our
study. According to definition for metabolic syndrome sug-
gested by the National Cholesterol Education Program Adult
Treatment Panel III (33), abdominal obesity is one of the diag-
nostic criteria of the metabolic syndrome. Increased adiposity
in the abdominal area may result in the development of insulin
resistance, so abdominal obesity estimated by waist circum-
ference, is inverse correlation with plasma adiponectin levels.
This study has some limitations. One limitation of this
study is that the diagnosis of NAFLD was based on ultra-
sound examination, but was not confirmed pathologically.
It is difficult to perform extensively in subjects with NAFLD,
mainly for ethical reasons (34). Some prospective study com-
paring ultrasound scanning with histological examination
indicated ultrasound scanning accurately identified steatosis
with a sensitivity of 94% and a specificity of 84% (35). Recent
study among biopsy proven NASH subjects also reported
those patients had lower adiponectin levels and higher HOMA-
IR than those with simple steatosis (24). Another limitation
is that our study had a cross-sectional design, and there was
potential bias in participation, so it cannot elucidate mecha-
nisms or determine the direction of causality.
In conclusion, we demonstrated that hypoadiponectinemia
and insulin resistance are associated with NAFLD indepen-
dent of total heaviness and abdominal fat distribution. Adi-
ponectin may be applicable in human disease as a novel agent
for treating insulin resistance including NAFLD in the future.
Further research is needed to identify the key determinants
of circulating adiponectin and the development of NAFLD.
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